Engineered immune cells take aim at hard-to-treat cancers in early trial

This early-phase trial tested a personalized cell therapy for adults with advanced cancers (stomach, breast, lung, cervical, and others) that carry a protein called KK-LC-1. Researchers took participants' own immune cells, modified them in the lab to better recognize and attack cancer, and infused them back along with a drug to help the cells survive. The main goal was to find the safest dose and check for side effects. The study was terminated early, so final results are limited.